Trial Profile
A Randomized, Controlled, Multicentre Trial of Collateral Damage on the Intestinal Microbiota Inferred by Temocillin Versus Cefotaxime in Patients Receiving Empirical Treatment for Febrile Urinary Tract Infections
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 May 2022
Price :
$35
*
At a glance
- Drugs Temocillin (Primary) ; Cefotaxime
- Indications Urinary tract infections
- Focus Adverse reactions
- 12 Sep 2019 Status changed from recruiting to completed.
- 15 Jun 2018 Planned End Date changed from 1 Sep 2018 to 1 Jun 2019.
- 15 Jun 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Mar 2019.